Literature DB >> 3507659

Identification and quantification of subsets of mononuclear inflammatory cells in melanocytic and other human tumors.

M S Nestor1, A J Cochran.   

Abstract

We used monoclonal antibodies and an indirect immunoperoxidase technique to identify mononuclear inflammatory cells associated with human tumors. The absolute number of the different types of inflammatory cells was assessed by using a point-counting technique. We studied tissues from six primary cutaneous melanomas, six metastatic melanomas, eight melanocytic nevi, 14 breast cancers, seven examples of fibrocystic disease of the breast, 11 lung cancers, and six colon cancers. Virtually all tumors were associated with substantial numbers of T lymphocytes (Leu3a-positive T helper-inducer cells predominating) and macrophages. Primary melanomas contained significantly more T lymphocytes (P less than .002), macrophages (P less than .005), and Langerhans/dendritic cells (P less than .002) than nevi or normal skin and had a higher proportion of T cells than metastatic melanomas (P less than .01). Breast cancers contained more T lymphocytes and macrophages than occur with fibrocystic disease (P less than .0001 and P less than .002, respectively) and more B lymphocytes. Cancers of the lung and colon contained moderate numbers of T lymphocytes and macrophages; however, colon cancers contained a higher proportion of B cells. Leu7-positive NK/K cells were noted in small numbers in all tumors examined.

Entities:  

Mesh:

Year:  1987        PMID: 3507659     DOI: 10.1111/j.1600-0749.1987.tb00530.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  2 in total

1.  Expression of monocyte chemotactic protein-1 in human melanoma in vivo.

Authors:  D T Graves; R Barnhill; T Galanopoulos; H N Antoniades
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

2.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.